Evidence map›Paper›PMID 24686850›Full record

ArticleNature genetics2014

Genomic and molecular characterization of esophageal squamous cell carcinoma.

De-Chen Lin, Jia-Jie Hao, Yasunobu Nagata, Liang Xu, Li Shang, Xuan Meng, Yusuke Sato, Yusuke Okuno, Ana Maria Varela, Ling-Wen Ding and 15 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 388 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
388citing papers in PubMed, 1 pooled it
49.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

388 citing papers in PubMed, 1 synthesis or guideline pooled it, 660 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Downregulation ofJournal of thoracic disease · 2026
    Article
  11. Esophageal cancer: from pathogenesis to precision therapies.Signal transduction and targeted therapy · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

328 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 8 institutions in 4 countries.

De-Chen Lin1] Cedars-Sinai Medical Center, Division of Hematology/Oncology, University of California Los Angeles School of Medicine, Los Angeles, California, USA. [2] Cancer Science Institute of Singapore, National University of Singapore, Singapore. [3].
Jia-Jie Hao1] State Key Laboratory of Molecular Oncology, Cancer Institute (Hospital), Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. [2].
Yasunobu Nagata1] Cancer Genomics Project, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. [2].
Liang Xu1] Cancer Science Institute of Singapore, National University of Singapore, Singapore. [2].
Li ShangState Key Laboratory of Molecular Oncology, Cancer Institute (Hospital), Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Xuan MengCancer Science Institute of Singapore, National University of Singapore, Singapore.
Yusuke SatoCancer Genomics Project, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Yusuke OkunoCancer Genomics Project, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.ORCID 0000000331399272
Ana Maria VarelaCancer Science Institute of Singapore, National University of Singapore, Singapore.
Ling-Wen DingCancer Science Institute of Singapore, National University of Singapore, Singapore.
Manoj GargCancer Science Institute of Singapore, National University of Singapore, Singapore.
Li-Zhen LiuCancer Science Institute of Singapore, National University of Singapore, Singapore.
Henry YangCancer Science Institute of Singapore, National University of Singapore, Singapore.
Dong YinMedical Research Center, Sun Yat-Sen Memorial Hospital, Guangzhou, China.
Zhi-Zhou ShiState Key Laboratory of Molecular Oncology, Cancer Institute (Hospital), Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Yan-Yi JiangState Key Laboratory of Molecular Oncology, Cancer Institute (Hospital), Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Wen-Yue GuState Key Laboratory of Molecular Oncology, Cancer Institute (Hospital), Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Ting GongState Key Laboratory of Molecular Oncology, Cancer Institute (Hospital), Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Yu ZhangState Key Laboratory of Molecular Oncology, Cancer Institute (Hospital), Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Xin XuState Key Laboratory of Molecular Oncology, Cancer Institute (Hospital), Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Ori KalidKaryopharm Therapeutics, Natick, Massachusetts, USA.
Sharon ShachamKaryopharm Therapeutics, Natick, Massachusetts, USA.
Seishi OgawaCancer Genomics Project, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Ming-Rong WangState Key Laboratory of Molecular Oncology, Cancer Institute (Hospital), Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
H Phillip Koeffler1] Cedars-Sinai Medical Center, Division of Hematology/Oncology, University of California Los Angeles School of Medicine, Los Angeles, California, USA. [2] Cancer Science Institute of Singapore, National University of Singapore, Singapore. [3] National University Cancer Institute, National University Hospital Singapore, Singapore.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNNational University of Singapore · SGThe University of Tokyo · JPKaryopharm Therapeutics (United States) · USCedars-Sinai Medical Center · USNational University Cancer Institute, Singapore · SGSun Yat-sen University · CNTokyo University of Technology · JP

Funding

REGULATION OF HEMATOPOIETIC CYTOKINESR01CA026038 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KOEFFLER, HAROLD PHILLIP · 1985 to 2013
$4.7M
NCI NIH HHS R01 CA026038NCI NIH HHS R01CA026038-35
6 · The paper itself

Abstract

Esophageal squamous cell carcinoma (ESCC) is prevalent worldwide and particularly common in certain regions of Asia. Here we report the whole-exome or targeted deep sequencing of 139 paired ESCC cases, and analysis of somatic copy number variations (SCNV) of over 180 ESCCs. We identified previously uncharacterized mutated genes such as FAT1, FAT2, ZNF750 and KMT2D, in addition to those already known (TP53, PIK3CA and NOTCH1). Further SCNV evaluation, immunohistochemistry and biological analysis suggested their functional relevance in ESCC. Notably, RTK-MAPK-PI3K pathways, cell cycle and epigenetic regulation are frequently dysregulated by multiple molecular mechanisms in this cancer. Our approaches also uncovered many druggable candidates, and XPO1 was further explored as a therapeutic target because it showed both gene mutation and protein overexpression. Our integrated study unmasks a number of novel genetic lesions in ESCC and provides an important molecular foundation for understanding esophageal tumors and developing therapeutic targets.

Indexed as

AnimalsBase SequenceCarcinoma, Squamous CellCell Line, TumorDNA Copy Number VariationsEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaExomeExportin 1 ProteinGenetic VectorsHEK293 CellsHigh-Throughput Nucleotide SequencingHumansImage Processing, Computer-AssistedImmunohistochemistryIn Situ Hybridization, FluorescenceExportin 1 ProteinKaryopherinsReceptors, Cytoplasmic and Nuclear

Identifiers

PMID24686850
PMCPMC4070589
OpenAlexW2020534880

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.